A Clinical Approach to Integrative Care Explained for OUD Treatment

Learn how the clinical approach to integrative care for OUD enhances recovery through multidisciplinary support and personalized treatments.

Abstract

This educational post aims to provide a comprehensive and compassionate understanding of Opioid Use Disorder (OUD) from an integrative healthcare perspective. My goal is to take you on a journey through the complex history of opioids, demystify the science behind them, and dismantle the persistent stigma that creates significant barriers to effective treatment. We will delve into the neurobiology of substance use, exploring how opioids impact the brain and why OUD is classified as a chronic medical condition, not a moral failing. I will present the latest evidence-based treatment recommendations, including both pharmacological and non-pharmacological approaches, grounded in the work of leading researchers. This guide will thoroughly explain the mechanisms of action for medications like buprenorphine, methadone, and naltrexone, and detail practical, life-saving harm reduction strategies such as naloxone co-prescribing. Furthermore, I will share how our unique multidisciplinary model at Injury Medical Clinic integrates integrative chiropractic care, functional medicine, and conventional medical oversight to provide holistic, patient-centered care. We will explore how this collaborative approach, which includes the invaluable expertise of our Medical Director, Dr. Maria Guadalupe Cardenas, MD, addresses the multifaceted nature of pain, recovery, and overall wellness.

Our Collaborative Care Model: Integrating Chiropractic, Medical, and Functional Medicine

Before we dive into the specifics of opioid use disorder, I want to take a moment to introduce the philosophy that guides my practice, Injury Medical Clinic, PA, here in El Paso, Texas. My name is Dr. Alex Jimenez, and my journey in healthcare has led me to accumulate a diverse set of credentials (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST). This background allows me to view patient health through multiple lenses—from the body’s structural alignment to its intricate biochemical pathways.

A cornerstone of our practice is our multidisciplinary and integrative approach. We believe that the most effective and sustainable healing comes from treating the whole person, not just a single symptom or condition. This is why I am honored to work alongside Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected, board-certified Internist with over 40 years of profound experience in the medical field. As our Medical Director and Collaborative Physician (NPI #1164426749, Texas MD License #J2933), she provides essential medical oversight, ensuring our patients receive holistic care grounded in the highest standards of medical safety and efficacy.

This collaborative structure is common and highly effective in modern integrative and injury care settings. It allows us to seamlessly blend the benefits of integrative chiropractic care with robust medical management. At our clinic, this synergy manifests in several ways:

• Comprehensive Diagnostics: A patient presenting with chronic pain, a common precursor to opioid use, receives a thorough evaluation from both a chiropractic and a medical perspective. I might assess musculoskeletal imbalances, spinal misalignments, and nerve impingement. At the same time, Dr. Cardenas reviews their medical history, orders relevant lab work, and evaluates for underlying systemic conditions that could contribute to their pain.
• Holistic Pain Management: Instead of defaulting to prescription medications, we create a layered treatment plan. This can include chiropractic adjustments to restore proper biomechanics and relieve nerve pressure, functional medicine strategies to reduce systemic inflammation through diet and targeted supplementation, and rehabilitation exercises to improve strength and stability. If medication is necessary, it is prescribed judiciously under Dr. Cardenas’s medical supervision, with a clear plan for tapering and integration with non-pharmacological therapies.
• Functional Medicine Integration: We dig deep to find the “why” behind a patient’s health issues. For someone struggling with OUD, this means looking beyond the substance use itself. We investigate potential gut-health imbalances, nutritional deficiencies, hormonal dysregulation, and environmental toxin exposures that can impact mood, cravings, and the body’s ability to heal.
• Support for Recovery: For patients on the path to recovery from OUD, our integrative model provides crucial support. Chiropractic care can help alleviate the physical discomfort and anxiety that often accompany withdrawal and early recovery. Functional medicine can help restore the neurochemistry that has been altered by long-term opioid use, supporting mental clarity and emotional stability. All of this is done in a supportive, non-judgmental environment, with the combined expertise of our entire team guiding the patient’s journey.

By weaving these different disciplines together, we offer a robust framework of care that honors the complexity of human health. It is this very framework that informs my approach to understanding and treating the profound challenge of opioid use disorder.

A Journey Through Time: Understanding the History of Opioids

To truly grasp the scope of the current opioid crisis, we must first look back at its origins. The story of opioids is a long and complex one, stretching back thousands of years and marked by moments of medical breakthrough, societal change, and devastating consequences. Understanding this history is not merely an academic exercise; it provides crucial context for the clinical and legislative landscape we navigate today.

The Different Faces of Opioids

Before we embark on this historical journey, we must define our terms. The word “opioid” is an umbrella term for a class of drugs that interact with opioid receptors in the body and brain. However, they are not all created equal. They fall into three main categories based on their origin:

• Natural Opioids (Opiates): These are substances derived directly from the resin of the opium poppy plant, Papaver somniferum. They are the original form of this drug class and have been used by humans for millennia. The most well-known examples are morphine and codeine.
• Semi-Synthetic Opioids: These are created in a laboratory but start with a natural opiate as their base. Chemists modify the structure of the natural substance to alter its potency, duration of action, or other properties. This category includes some of the most commonly prescribed and misused drugs, such as heroin (synthesized from morphine), oxycodone, and hydrocodone.
• Synthetic Opioids: These are entirely manufactured in a laboratory, with no connection to the opium poppy. Their chemical structures are designed to mimic the effects of natural opiates by binding to the same opioid receptors. This group includes medications like methadone and, most notably, fentanyl and its exceptionally potent analogs.

A Chronological Overview

The timeline of opioid use is a stark illustration of how a natural substance used for relief evolved into a global public health emergency.

• 3400 BC: The earliest recorded cultivation of the opium poppy occurs in Mesopotamia. The Sumerians refer to it as “Hul Gil,” the “joy plant,” recognizing its euphoric and sedating properties.
• 1400s AD: Following centuries of use in various cultures, opium gains prominence as a pain reliever among the Greeks and Romans. It is prepared in various tinctures and potions.
• 1500s: Paracelsus, a Swiss physician and alchemist, popularizes the use of laudanum—an alcoholic tincture of opium—to treat a wide range of ailments, including diarrhea and pain. This marks one of the first widespread medical applications in Europe.
• 1803: A pivotal moment in pharmacology occurs when German chemist Friedrich Sertürner successfully isolates the primary active alkaloid from opium. He names it morphine after Morpheus, the Greek god of dreams. This discovery allows for standardized dosing and more potent pain relief, revolutionizing surgery and medicine.
• 1832: French chemist Pierre-Jean Robiquet isolates another alkaloid from opium, codeine. It is found to be less potent than morphine and proves to be an effective cough suppressant, becoming a common ingredient in tonics and elixirs.
• 1874: In a search for a less addictive alternative to morphine, English chemist C.R. Alder Wright synthesizes diacetylmorphine by boiling morphine with acetic anhydride. The German pharmaceutical company Bayer would later market this substance in 1898 under the trade name heroin, initially promoting it as a “non-addictive” cough suppressant and morphine substitute.
• 1939: During World War II, German scientists Max Bockmühl and Gustav Ehrhart synthesized a new compound while searching for a painkiller that could be easily produced with readily available precursors. This synthetic opioid became known as methadone. Its long half-life would later make it a cornerstone of opioid addiction treatment.
• 1959: Belgian chemist Dr. Paul Janssen synthesizes fentanyl. This powerful synthetic opioid is found to be 50 to 100 times more potent than morphine. It is initially developed for use as an intravenous anesthetic and for managing severe cancer pain, particularly through transdermal patches.
• 1966: Researchers at a British consumer goods company, Reckitt & Colman (now Reckitt), discover buprenorphine. This unique compound is identified as a partial agonist, a property that would later make it a safer and more accessible option for treating opioid use disorder.

This timeline reveals that while opioids have ancient roots, the development of the most potent and widely used semi-synthetic and synthetic forms is a relatively recent phenomenon, concentrated within the last 200 years. This rapid pharmacological evolution has dramatically outpaced our society’s ability to manage its consequences.

Understanding Potency: The Concept of Morphine Milligram Equivalents (MME)

When we discuss and prescribe different opioids, it is not enough to compare dosages in milligrams. The potency of these drugs varies enormously. To standardize the risk assessment and dosing, healthcare providers use a metric called Morphine Milligram Equivalents (MME). This value converts the dosage of any opioid into the equivalent dosage of oral morphine, providing a common benchmark for evaluating the total opioid load a patient is receiving and their associated risk of overdose.

Here is a look at the relative potencies of common opioids, ordered from least to most potent, based on their MME conversion factors. Clinicians must be intimately familiar with these conversions.

• Tramadol: MME = 0.1. This means 10 milligrams of tramadol is equivalent to 1 milligram of morphine.
• Codeine: MME = 0.15. It is slightly more potent than tramadol.
• Hydrocodone: MME = 1. This opioid, commonly found in medications like Vicodin or Norco, has a 1:1 potency with oral morphine.
• Oxycodone: MME = 1.5. This drug, the active ingredient in OxyContin and Percocet, is 50% more potent than morphine. A 20mg dose of oxycodone is equivalent to 30mg of morphine.
• Hydromorphone (Dilaudid): MME = 4. This semi-synthetic opioid is four times as potent as morphine.
• Fentanyl (Transdermal): The conversion for fentanyl is more complex and based on micrograms. A transdermal patch delivering 12.5 micrograms per hour is roughly equivalent to 30 MME per day. The intravenous form is even more potent. Its high potency is a primary driver of the current overdose crisis, as even minuscule amounts can be lethal, especially for an opioid-naïve individual.

From a clinical standpoint, understanding MME is paramount. Guidelines from the Centers for Disease Control and Prevention (CDC) have historically recommended using caution when prescribing >50 MME/day and avoiding or carefully justifying >90 MME/day for chronic non-cancer pain due to the escalating risk of overdose.

The Three Waves of the U.S. Opioid Overdose Crisis

The opioid crisis in the United States did not emerge overnight. It has unfolded in three distinct and tragic waves, each characterized by a different primary driver of overdose deaths. Analyzing these waves helps us understand how the problem has evolved and why our response must keep adapting.

Wave 1: The Rise of Prescription Opioids (1999–2010)

The first wave began in the late 1990s, fueled by a perfect storm of factors. Pain was reframed as the “fifth vital sign,” leading to more aggressive pain management practices. Simultaneously, pharmaceutical companies launched powerful marketing campaigns for new extended-release opioid formulations, most notably OxyContin. These campaigns often downplayed the addiction risk of these medications.

• The Outcome: Between 1999 and 2010, the sale of prescription opioids in the United States quadrupled. As the volume of pills flooding communities increased, so did the rates of misuse, addiction, and overdose. During this period, overdose deaths involving prescription opioids (excluding synthetic opioids like fentanyl) more than doubled, rising from approximately 2.9 to 6.8 deaths per 100,000 people. Many individuals who later developed a more severe substance use disorder first became dependent on legitimately prescribed medications.

Wave 2: The Resurgence of Heroin (2010–2013)

As awareness of prescription opioid addiction grew, state and federal agencies began to implement stricter prescribing guidelines, create prescription drug monitoring programs (PDMPs), and encourage the reformulation of drugs like OxyContin to make them more difficult to crush and inject. While well-intentioned, these measures had an unintended consequence.

• The Outcome: Individuals who were already dependent on prescription opioids found their supply either cut off or too expensive on the illicit market. At the same time, the illicit market was flooded with cheaper and more readily available heroin. Many people transitioned from misusing pills to using heroin to manage their dependence and avoid withdrawal. From 2010 to 2013, heroin-involved overdose deaths skyrocketed, increasing from 1.0 to 4.9 per 100,000 people. By the end of this period, deaths from heroin had surpassed those from prescription opioids.

Wave 3: The Dominance of Synthetic Opioids (2013–Present)

The third and most lethal wave began around 2013 with the infiltration of illicitly manufactured fentanyl and its analogs into the drug supply. Fentanyl is incredibly potent (50- 100 times stronger than morphine) and cheap to produce, making it an attractive and profitable adulterant for drug traffickers. It began to be mixed into heroin, often without the user’s knowledge. Now, it is frequently pressed into counterfeit pills made to look like legitimate prescription opioids (like oxycodone or Xanax) or even mixed into stimulants like cocaine and methamphetamine.

• The Outcome: The impact has been catastrophic. From 2013 to 2018 alone, overdose deaths involving synthetic opioids increased by over 1,000%, soaring from 1.0 to 11.4 per 100,000 people. This wave has completely eclipsed the previous two, as shown in the CDC graph below. A disturbing recent trend within this wave is the emergence of xylazine, a non-opioid animal tranquilizer, as an adulterant in the fentanyl supply. Xylazine, also known as “tranq,” does not respond to naloxone and causes severe necrotic skin ulcers, complicating overdose response and wound care. The presence of xylazine in up to 10% of fentanyl-related overdoses highlights the constantly evolving and increasingly dangerous nature of the illicit drug market.

In response to this escalating crisis, the U.S. Department of Health and Human Services officially declared the opioid crisis a public health emergency in October 2017. This declaration remains in effect today.

Visualizing the Crisis: A Look at the Data

The graph from the CDC starkly visualizes these three waves.

• The teal line represents overdose deaths from commonly prescribed opioids. You can see it rise steadily from 1999, then plateau and even slightly decline as regulations tightened.
• The dark blue line shows the rise of heroin, beginning its sharp ascent around 2010.
• The purple line, representing synthetic opioids like fentanyl, is the most dramatic. It remains relatively flat until 2013, at which point it begins an exponential climb, dwarfing the other two categories and driving the overall increase in overdose deaths to unprecedented levels.

This visual data is a powerful and sobering testament to the scale of the challenge we face.

The Current Landscape of Opioid Misuse

To understand the full picture, we must also look at the prevalence of misuse. Data from the 2021 National Survey on Drug Use and Health (SAMHSA) provides a snapshot of opioid misuse among people aged 12 and older in the United States.

• Overall Misuse: An estimated 2 million people misused opioids in the past year.
• Pain Reliever Misuse: The vast majority of this misuse involves prescription pain relievers. Approximately 8.7 million people misused these medications.
• Heroin Use: About 1.1 million people used heroin.
• Overlap: There is an overlap of about half a million people who reported misusing both prescription pain relievers and heroin.

This data underscores a critical point for all healthcare providers: while heroin and fentanyl drive the majority of overdose deaths, the misuse of prescribed pain relievers remains a widespread problem. This reinforces the need for vigilant screening, patient education, and a commitment to responsible prescribing practices across all fields of medicine, from surgery to primary care to chiropractic.

The Legal and Treatment Framework: A History of Policy Milestones

The way we treat opioid use disorder has been shaped as much by legislation as by medical science. This legislative history reflects a slow, often fraught, evolution in our societal understanding—from viewing addiction as a crime to recognizing it as a treatable medical condition.

• 1914 – Harrison Narcotics Tax Act: This was one of the first major federal laws to regulate opiates and cocaine. It required manufacturers, doctors, and pharmacists to register and pay a tax. While ostensibly a tax law, its enforcement effectively criminalized the non-medical use of opiates and drove addiction underground. It also restricted physicians from prescribing opioids to maintain a person’s dependence, a move that dismantled early maintenance clinics.
• 1970 – Controlled Substances Act (CSA): This landmark act created the drug scheduling system (Schedules I through V) that we use today to classify drugs based on their medical use and potential for abuse. It also established the Drug Enforcement Administration (DEA) to enforce these regulations. This act solidified the federal government’s role in regulating both illicit drugs and controlled prescription medications.
• 1974 – Narcotic Addiction Treatment Act: This act established the regulatory framework for what we now know as Opioid Treatment Programs (OTPs), or “methadone clinics.” It mandated that methadone for the treatment of opioid addiction could only be dispensed through these highly regulated, federally certified programs, restricting its use in general medical practice.
• 2000 – Drug Addiction Treatment Act (DATA 2000): This was a revolutionary piece of legislation. It created the “buprenorphine waiver,” or “X-waiver.” For the first time, it allowed qualified physicians who completed a specific 8-hour training to prescribe a Schedule III opioid—buprenorphine—for the treatment of opioid use disorder directly from their offices. This “office-based opioid treatment” (OBOT) was a paradigm shift, moving treatment out of the specialized clinic and into mainstream medical settings like primary care.
• 2016 – Comprehensive Addiction and Recovery Act (CARA): This act expanded on DATA 2000 by granting prescribing authority for buprenorphine to Nurse Practitioners (NPs) and Physician Assistants (PAs) after they completed 24 hours of required training. This was a critical step in expanding the workforce of providers who can offer this life-saving treatment, especially in underserved rural areas.
• 2018 – SUPPORT for Patients and Communities Act: This comprehensive bipartisan legislation further expanded access to treatment by, among other things, making permanent the ability of NPs and PAs to prescribe buprenorphine and expanding care coverage for OUD treatment under Medicare and Medicaid.
• 2023 – Mainstreaming Addiction Treatment (MAT) Act: In another monumental shift, this act, passed as part of the Consolidated Appropriations Act of 2023, eliminated the buprenorphine waiver (the X-waiver). This means that any prescriber with a standard DEA license who is authorized by their state to prescribe Schedule III medications can now prescribe buprenorphine for opioid use disorder. This legislation aims to fully “mainstream” addiction treatment by removing the unique federal barrier that set it apart from the treatment of any other medical condition.

This legislative journey charts a clear path toward integrating addiction medicine into the fabric of general healthcare, a goal that my practice wholeheartedly embraces.

The Rationale for Treatment: Why We Must Act

The statistics surrounding opioid use disorder are staggering and paint a clear picture of a public health crisis that demands an urgent and comprehensive response from the entire healthcare system.

• The Treatment Gap: In the United States, an estimated 9 million adults meet the criteria for opioid use disorder and could benefit from treatment. However, only a little over 2 million actually receive medications for opioid use disorder (MOUD). This vast gap between need and access represents millions of missed opportunities to save lives.
• Disparities in Care: The data reveals significant disparities in who receives treatment. White males aged 35 to 49 are the demographic most likely to receive MOUD. This highlights systemic barriers and inequities that prevent women, younger and older adults, and people from racial and ethnic minority groups from accessing care.
• The Human Cost: The numbers are more than just statistics; they represent individual lives lost and families devastated. In 2022 alone, there were nearly 82,000 opioid-involved overdose deaths. This is equivalent to a jumbo jet crashing every single day of the year.
• The Economic Impact: The societal cost of the opioid crisis is immense, estimated to be over $193 billion annually. This figure includes costs related to healthcare, lost productivity, addiction treatment, and criminal justice involvement.

These numbers make an undeniable case: treating opioid use disorder is not optional. It is a medical, ethical, and economic imperative. As healthcare providers, we are on the front lines and have a professional responsibility to be part of the solution.

Dismantling Myths and Stigma in Healthcare

To effectively treat OUD, we must first confront and dismantle the deeply ingrained myths and stigma that permeate our culture and, unfortunately, our healthcare system. These stigmatizing beliefs create barriers to care, foster shame in patients, and prevent providers from offering evidence-based treatment. Let’s address some of the most common and damaging myths.

Myth 1: “Medications for OUD (MOUD) just replace one addiction with another.”

The Truth: This is perhaps the most pervasive and harmful myth. To debunk it, I often ask colleagues to reframe it in the context of another chronic disease, like diabetes. We would never say that prescribing insulin for a person with Type 1 diabetes is “replacing their sugar addiction with an insulin addiction.” It is understood as providing a life-saving medication to correct a physiological deficit.

Similarly, MOUD works by stabilizing the brain’s neurochemistry, which has been profoundly altered by long-term opioid use. Medications like buprenorphine and methadone occupy the opioid receptors, which reduces or eliminates debilitating withdrawal symptoms and cravings. This stabilization allows the patient to disengage from the chaotic, all-consuming cycle of seeking and using illicit drugs. It enables them to focus on rebuilding their life: holding a job, repairing relationships, and engaging in therapy. MOUD is not a “crutch”; it is the foundation upon which recovery is built.

Myth 2: “Recovery without medication is a superior or ‘truer’ form of recovery.”

The Truth: This belief creates a false and dangerous hierarchy of recovery pathways. Let’s return to a different medical analogy: hypertension. Imagine two patients with high blood pressure. We advise both to start with diet and exercise. Patient A successfully lowers their blood pressure with these lifestyle changes alone. Patient B, despite their best efforts with diet and exercise, still has dangerously high blood pressure, so we add a medication like a beta-blocker.

Would we ever consider Patient A’s treatment plan “superior” to Patient B’s? Of course not. We would recognize that two different patients required two different, individualized treatment plans to achieve the same medical goal: a healthy blood pressure. The same logic applies to OUD. The goal is recovery and well-being. For many, MOUD is the most effective, and often necessary, tool to achieve that goal. Judging one pathway as inferior to another is stigmatizing and clinically unsound.

Myth 3: “MOUD is not effective.”

The Truth: This is patently false and contradicted by decades of overwhelming scientific evidence. The literature is unequivocal: MOUD is the gold standard of care for opioid use disorder. Most notably, studies have consistently demonstrated that treatment with buprenorphine or methadone is associated with a dramatic reduction in all-cause mortality. Some studies show this reduction to be as high as 50-60%. MOUD significantly decreases the risk of fatal overdose, reduces the transmission of HIV and Hepatitis C, lowers criminal justice involvement, and improves overall health and social functioning. Denying or discouraging access to MOUD is to ignore the most effective life-saving intervention we have for this disease.

Myth 4: “MOUD is a crutch for ‘weak’ people who can’t stop on their own.”

The Truth: This statement reflects a fundamental misunderstanding of the neurobiology of addiction. Opioid use disorder is a chronic brain disease, not a failure of willpower. Prolonged use of opioids literally hijacks the brain’s reward and decision-making circuits. The prefrontal cortex, the part of the brain responsible for judgment, impulse control, and long-term planning, becomes impaired. Meanwhile, the midbrain’s survival and reward pathways become pathologically rewired to prioritize obtaining and using the substance above all else—including food, safety, and relationships.

In this state, a person’s capacity for choice is severely compromised. They are not “choosing” to continue using in the face of negative consequences; they are contending with a brain that is sending powerful, overwhelming signals that the substance is necessary for survival. MOUD helps to correct this neurobiological dysfunction, restoring the brain to a state where rational decision-making is once again possible. It is a medical treatment for a medical disease.

Defining the Disease: What is a Substance Use Disorder?

To move past the stigma, we need a clear, clinical definition of the condition we are treating. In the past, you may have heard terms like “abuse,” “dependence,” or “addiction.” The current clinical standard, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), is the term Substance Use Disorder (SUD).

An SUD is defined as a chronic, relapsing medical condition characterized by a problematic pattern of substance use leading to clinically significant impairment or distress. The diagnosis is made based on a specific set of 11 criteria, and the severity of the disorder is categorized based on how many criteria an individual meets:

• Mild: 2-3 criteria
• Moderate: 4-5 criteria
• Severe: 6 or more criteria

The good news is that, despite its severity, SUD is treatable, and a wide array of evidence-based treatments are available.

The 11 DSM-5 Criteria for Opioid Use Disorder

Looking closely at the diagnostic criteria is illuminating because it shows the diagnosis is not based on the quantity or frequency of use, but on the impact use has on a person’s life, behavior, and health. A patient must meet at least two of these criteria within a 12-month period to be diagnosed with OUD.

1. Using in larger amounts or for a longer period than intended. (e.g., “I only meant to take one pill, but I ended up taking four,” or “I planned to use just for the weekend, but now it’s been two weeks.”)
2. A persistent desire or unsuccessful efforts to cut down or control use. (e.g., “I’ve tried to quit so many times, but I just can’t.”)
3. Spending a great deal of time obtaining, using, or recovering from the effects of the substance. This criterion highlights how the substance becomes the central organizing principle of a person’s life.
4. Craving, or a strong desire or urge to use. This is a powerful, intrusive thought process that can be overwhelming.
5. Recurrent use resulting in failure to fulfill major role obligations at work, school, or home. (e.g., losing a job, failing classes, neglecting children).
6. Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance. (e.g., arguments with family, losing friends).
7. Giving up or reducing important social, occupational, or recreational activities because of use. The person’s world shrinks, and activities that once brought joy are abandoned.
8. Recurrent use in situations in which it is physically hazardous. (e.g., driving while impaired, sharing needles).
9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. This key criterion demonstrates the “hijacking” of the brain. The person knows the use is harming them (e.g., causing liver damage, worsening their depression), but they are unable to stop.
10. This is defined by either (a) a need for markedly increased amounts of the substance to achieve the desired effect, or (b) a markedly diminished effect with continued use of the same amount.
11. This is manifested by either (a) the characteristic opioid withdrawal syndrome, or (b) taking an opioid (or a closely related substance) to relieve or avoid withdrawal symptoms.

It is crucial to note that tolerance and withdrawal (criteria 10 and 11) alone do not constitute an OUD. A patient taking opioids as prescribed for chronic pain will develop physical dependence (tolerance and withdrawal). This is a normal physiological adaptation. An OUD is diagnosed only when these are accompanied by at least one of the first nine criteria, which reflect the pathological, compulsive patterns of use and negative life consequences.

The Pervasive Impact of Stigma on Care

Stigma is not just hurtful words or attitudes. It is a powerful social force that has tangible, life-threatening consequences for people with opioid use disorder. It manifests at every level of society and directly impacts health outcomes.

Public Stigma

Public stigma refers to the negative attitudes and beliefs held by the general population.

• Misunderstanding the Disease: A primary driver of public stigma is the failure to recognize SUD as a chronic medical condition. When viewed as a moral failing, individuals with SUD are blamed for their illness.
• Association with Crime: People with OUD are often stereotyped as dangerous, untrustworthy, and associated with criminal activity.
• Opposition to Treatment Access: This stigma translates into political opposition to policies that would increase access to care, such as placing treatment clinics or implementing harm reduction programs like syringe service centers. This is often called the “Not In My Backyard” (NIMBY) phenomenon.
• Correlation with Age: Some studies suggest that stigmatizing attitudes tend to increase with age, indicating a generational gap in understanding addiction as a disease.

Structural Stigma

Structural stigma is when the patterns of public stigma become embedded in institutions, policies, and laws.

• The “War on Drugs”: Declared in 1971, this policy framework prioritized criminalization over public health. It led to mass incarceration, disproportionately affecting racial and ethnic minorities, without providing adequate SUD treatment within the criminal justice system. It fundamentally framed addiction as a crime to be punished rather than a disease to be treated.
• The Buprenorphine “X-Waiver”: As discussed earlier, the very existence of a special waiver required for providers to prescribe buprenorphine, while no such extra training was needed to prescribe the opioids that often caused the problem, was a form of structural stigma. It signaled that treating addiction was somehow different, more difficult, or riskier than treating any other condition. The elimination of the waiver in 2023 was a major step toward dismantling this structural barrier.
• Funding and Policy Barriers: A chronic lack of funding for mental health and SUD services creates massive gaps in care. Furthermore, organizational policies, such as stringent drug testing requirements for employment or housing, can be highly stigmatizing and punitive, making it harder for people in recovery to rebuild their lives.

Individual and Internalized Stigma

This is the stigma that individuals hold, both toward others and toward themselves.

• Provider Bias: Unfortunately, healthcare providers are not immune to holding stigmatizing beliefs. Studies have shown that some providers view SUD as a moral failing rather than a medical condition. This bias is correlated with a reduced likelihood of prescribing MOUD. Providers may also express worry about the legal implications of treating this patient population or feel that these patients are “difficult” or “manipulative.”
• Stereotypes and Prejudice: Individual stigma manifests as stereotypes (e.g., people with OUD are dangerous and unpredictable), prejudice (e.g., feelings of moral outrage, anger, and fear), and discrimination (e.g., providing coercive or lower-quality care, or refusing to treat patients with OUD for other conditions).
• Internalized Shame: Perhaps most tragically, individuals with OUD often internalize these negative societal messages. They may come to believe that they are “less than,” weak, or fundamentally flawed. This internalized shame can be a major barrier to seeking help and can lead to feelings of hopelessness and despair. It can also create conflict within recovery communities, where some may be told they are not “truly sober” if they are taking medications for their OUD.

The Power of Language: Choosing Words that Heal

One of the most immediate and powerful ways we can begin to dismantle stigma is by changing the language we use. Person-first language is a simple but profound practice that reorients our thinking to see the person before the disease. It separates the person’s identity from their condition. Here are some key shifts we should all make in our clinical practice and daily conversations.

Instead of this (Stigmatizing Language)	Use this (Person-First Language)	Why it Matters
Addict, junkie, user	Person with a substance use disorder (SUD), Person in recovery, Person who uses drugs (PWUD), Person who injects drugs (PWID)	“Addict” defines a person by their disease. “Person with an SUD” acknowledges their humanity first. PWUD/PWID are neutral, descriptive terms used in public health.
Abuse	Misuse, Use	“Abuse” is a loaded, judgmental term associated with violence and wrongdoing. “Misuse” or “use” are more neutral, objective terms to describe the behavior.
Clean / Dirty (referring to drug tests)	Negative / Positive (e.g., “The result was negative for opioids,” or “The result was positive for fentanyl.”)	Labeling a person or their toxicology result as “dirty” is deeply shaming and dehumanizing. We would never call a diabetic’s blood “dirty” for having a high A1C. We state the clinical fact.
Addicted baby	Baby born with neonatal opioid withdrawal syndrome (NOWS)	A baby cannot be “addicted,” as addiction involves compulsive behaviors. A baby can, however, be born physically dependent on a substance used by the mother during pregnancy and experience a physiological withdrawal syndrome. NOWS is the accurate clinical term.
Medication-Assisted Treatment (MAT)	Medications for Opioid Use Disorder (MOUD)	The term “assisted” implies that medication is just a helper, secondary to the “real” treatment (like counseling). The evidence is clear: medication is the treatment. MOUD correctly frames medication as a primary, life-saving, first-line therapy.

Putting It Into Practice: A Case Study Rewritten

Let’s see the impact of this language shift by reviewing and revising a sample case presentation.

Original Stigmatizing Version:

Substance Use History: Patient reports abusing heroin IV from age 20 to 30. At age 20, she tried heroin with friends and began to use it daily soon after. Last use of heroin was one month ago after seven years clean.

Substance Use Treatment History: Entered recovery after an overdose. Started medication-assisted treatment.

Strengths and Protective Factors: Has a supportive family and is regularly involved with the addict community.

Family History: Father is living, with a history of OUD, in recovery for 30 years. Mother is living; history of diabetes. No siblings. She has one female child, age 9, born addicted to heroin, who is healthy now.

Now, let’s rewrite the same case using person-first, non-stigmatizing language.

Revised, Person-First Version:

Substance Use History: The patient reports misusing heroin via IV from ages 20 to 30. She began to use it daily after her initial use at age 20. Her last use of heroin was one month ago, following seven years of no use.

Substance Use Treatment History: She entered recovery after experiencing an overdose and started on medications for opioid use disorder (MOUD).

Strengths and Protective Factors: She has a supportive family and is regularly involved with the recovery community.

Family History: Father is living, with a history of OUD, in recovery for 30 years. Mother is living, with a history of diabetes. No siblings. She has one female child, age 9, who was born with neonatal opioid withdrawal syndrome (NOWS) and is healthy now.

The difference is palpable. The second version is more professional, respectful, and clinically precise. It presents the patient as a person with a medical history, not as a collection of negative labels. Adopting this language is a critical first step for any provider dedicated to compassionate, effective care.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Evidence-Based Treatment: A Patient-Centered Approach

Treating opioid use disorder effectively requires a multi-pronged approach that combines psychosocial support with medical treatment. A cornerstone of this approach is Motivational Interviewing (MI), a communication style that has proven exceptionally effective in helping people change their behavior.

The Heart of Treatment: Motivational Interviewing (MI)

Motivational Interviewing is not a specific type of therapy, but rather a “guiding” style of communication. It is a collaborative conversation designed to strengthen a person’s own motivation and commitment to change. It is profoundly patient-centered and fundamentally different from a traditional, directive approach where the provider tells the patient what to do.

The Spirit of MI

The practice of MI is grounded in a specific mindset or “spirit,” which can be summarized by four key elements:

1. Partnership: The provider is not the expert on the patient’s life; the patient is. The relationship is a collaboration. You are a supportive partner, not a persuasive authority figure. You work with the patient, not on them.
2. Acceptance: This involves four components:

• • Absolute Worth: Recognizing that every patient has inherent worth and potential, regardless of their current behavior.
  • Autonomy: Respecting the patient’s right and capacity for self-direction. Ultimately, the decision to change (or not) is theirs.
  • Accurate Empathy: An active effort to understand the patient’s world from their perspective, without judgment.
  • Affirmation: Actively seeking out and acknowledging the patient’s strengths, positive intentions, and past efforts.

• Compassion: The provider’s primary commitment is to pursue the patient’s welfare and best interests. This requires being non-judgmental, non-blaming, and non-shaming.
• Evocation: The core belief of MI is that the motivation for change, and the resources to achieve it, reside within the patient. The provider’s job is not to install motivation, but to evoke it—to draw it out.

The Process of MI

The flow of a motivational interviewing conversation typically follows four overlapping processes:

1. Engaging: This is the foundation. It’s about building rapport and establishing a trusting, collaborative working relationship. This is where we demonstrate genuine curiosity and empathy.
2. Focusing: In this stage, the provider and patient collaborate to identify a clear target or goal for the conversation. What does the patient want to talk about? What change are they considering? The agenda is shared, not imposed.
3. Evoking: This is the heart of MI. The provider listens for and elicits the patient’s own arguments for change (“change talk”). You explore their reasons, their values, and their desire to change.
4. Planning: Once the patient’s motivation has been strengthened, the conversation can shift toward developing a concrete plan of action. This involves exploring options, creating a specific goal, and building support for the plan. The plan comes from the patient, with the provider acting as a knowledgeable resource.

Core Skills and Techniques of MI

MI provides a toolkit of skills and strategies to bring the spirit and process to life in a clinical encounter.

The OARS Acronym

OARS represents the four core communication skills used in MI:

• O – Open-Ended Questions: Questions that cannot be answered with a simple “yes” or “no.” They invite the patient to tell their story.

• • Example: Instead of “Are you thinking about cutting back?” ask, “What are your thoughts about your opioid use right now?” or “Tell me about your recovery journey so far.”

• A – Affirmations: These are statements that recognize the patient’s strengths, efforts, and positive attributes. They build confidence and rapport.

• • Example: “That’s a really creative idea for how to handle that trigger.” or “It took a lot of courage to come in today and talk about this.”

• R – Reflective Listening: This is arguably the most important skill in MI. A reflection is a statement that reflects the meaning of what the patient has said. It shows you are listening and helps the patient hear their own thoughts in a new way. A good MI conversation should have more reflections than questions.

• • Simple Reflection: Patient: “I’m just so tired of this whole mess.” Provider: “You’re feeling exhausted by it all.”
  • Complex Reflection: Patient: “My wife is threatening to leave me if I don’t stop, but I don’t know if I can.” Provider: “You’re feeling pulled in two directions. On one hand, your marriage is incredibly important to you, but on the other, the idea of quitting feels overwhelming.”

• S – Summaries: A summary is essentially a collection of reflections. It pulls together key themes from the conversation, reinforces what has been discussed, and can serve as a transition to the next topic.

• • Example: “Let me see if I’m understanding you correctly. You’ve been using heroin for about a year, and while it helps you cope with stress, you’re starting to see how it’s affecting your job and your health. You’re worried about your kids, and you’re starting to think about making a change, but you’re scared of the withdrawal. Is that about right?”

Eliciting “Change Talk” with DARN-CAT

The goal of evoking is to get the patient to voice their own arguments for change. This is called “change talk.” The more a person talks about changing, the more likely they are to do it. The acronym DARN-CAT helps us remember the different types of change talk to listen for and elicit.

DARN represents the preparatory phase of change talk:

• D – Desire: “I want to…” “I wish I could…”

• • Eliciting Question: “What do you hope our work together will accomplish?”

• A – Ability: “I could probably…” “I think I can…”

• • Eliciting Question: “If you did decide to make a change, what do you think might be a possible first step?”

• R – Reasons: “I would have more energy if I…” “My family would be happier if I…”

• • Eliciting Question: “What are some of the reasons you might want to stop or cut back your use?”

• N – Need: “I have to do something.” “I need to…”

• • Eliciting Question: “What needs to happen for you to feel ready to make a change?”

CAT represents mobilizing change talk, which signals the person is getting closer to action:

• C – Commitment: “I will…” “I promise…” “I am going to…”
• A – Activation: “I am ready to…” “I am prepared to…”
• T – Taking Steps: “I have already started…” “I went to a meeting this week.” “I called the clinic.”

As clinicians, our job is to listen for these whispers of change and use our OARS skills to amplify them.

Understanding the Stages of Change

Motivational interviewing is deeply connected to the Transtheoretical Model of Change, which posits that people move through a series of stages when modifying a behavior. Our approach must be tailored to the patient’s current stage.

1. Precontemplation: The person is not currently considering change. They may not see their behavior as a problem. (“I don’t think my drug use is impacting my life.”) The goal here is not to push for change, but to gently raise awareness and build rapport.
2. Contemplation: The person is ambivalent about change. They are simultaneously weighing the pros and cons. (“I think my marriage would improve if I reduce my drug use, but I’m not sure how I’d cope without it. “) The goal is to tip the balance in favor of change by exploring their values and reasons for change.
3. Preparation: The person is committed to changing and is beginning to take small steps toward it. (“I have looked up an NA meeting to attend near my house.”) The goal is to help them create a realistic and effective plan.
4. Action: The person is actively implementing their plan and changing their behavior. (“I started on buprenorphine last week.” or “I reduced the number of days per week I use drugs.”) The goal is to support them in their new behaviors and help them troubleshoot challenges.
5. Maintenance: The person has sustained their new behavior for a period of time (typically 6 months or more) and is working to prevent relapse. (“I have been on MOUD for a year now.”) The goal is to help them anticipate and cope with triggers and continue building a recovery-supportive lifestyle.

Understanding where a patient is on this continuum is vital. Pushing a precontemplative patient into action will only create resistance. Meeting them where they are is the key to a productive partnership.

The Role of Non-Pharmacological Management

While medication is a critical component of OUD treatment, it is most effective when combined with psychosocial support. In my practice, we emphasize a holistic approach that includes chiropractic care to address the physical manifestations of stress and pain, alongside these behavioral interventions.

• Behavioral Therapy: One-on-one counseling with a psychologist, social worker, or a certified recovery coach can be invaluable. These sessions provide a safe space to explore the root causes of substance use, develop coping skills, and address co-occurring mental health conditions like depression and anxiety.
• Group Therapy and Peer Support: Connection with others who have shared experiences is a powerful catalyst for recovery. There are many different models of group support:

• • 12-Step Programs: Narcotics Anonymous (NA) and Alcoholics Anonymous (AA) are well-known programs based on a 12-step model of recovery, which often includes a spiritual component of surrender to a “higher power.”
  • SMART Recovery (Self-Management and Recovery Training): A secular, science-based program that uses principles from Cognitive Behavioral Therapy (CBT) and Rational Emotive Behavior Therapy (REBT) to teach self-empowerment and self-reliance.
  • Secular Organizations for Sobriety (SOS): Another non-religious alternative to 12-step programs.

• Integrative Chiropractic Care: In our clinic, we have seen firsthand how chiropractic adjustments can support recovery. Many individuals with OUD also suffer from chronic pain—often the very reason they started taking opioids. Chiropractic care can address the underlying musculoskeletal issues contributing to this pain, reducing the physical impetus for opioid use. Furthermore, adjustments can help regulate the autonomic nervous system, reducing the “fight-or-flight” response associated with anxiety and cravings, and promoting a state of calm and well-being that is conducive to recovery.

It’s important to stress that while these therapies are highly encouraged, participation should never be a mandatory requirement for a patient to receive life-saving MOUD. We offer these as supportive options, respecting the patient’s autonomy to choose the path that works best for them. I strongly encourage fellow healthcare providers to observe a local recovery meeting. Many are open to the public, and attending one can provide invaluable insight into the supportive environment you are recommending to your patients.

Pharmacological Management: The Science Behind MOUD

To understand how medications for opioid use disorder work, we must first understand how opioids interact with the brain at a molecular level. The key players are the opioid receptors, particularly the mu-opioid receptor. When activated, this receptor is responsible for the primary effects of opioids: pain relief (analgesia), euphoria, and, dangerously, respiratory depression.

Different substances have different relationships with this receptor:

• Full Agonists: These substances bind to and fully activate the mu-opioid receptor, producing the maximum possible opioid effect. The dose-response curve is linear; as the dose increases, the effect increases. This category includes heroin, morphine, oxycodone, methadone, and fentanyl. This unlimited activation is what leads to a high risk of respiratory depression and overdose.
• Partial Agonists: These substances bind to the mu-opioid receptor but only partially activate it. The key example is buprenorphine. Even as the dose increases, it produces a less-than-maximal opioid effect. Crucially, it has a “ceiling effect,” meaning that beyond a certain dose, increasing the dose further does not increase the opioid effect. This ceiling is below the threshold for significant respiratory depression, making it a much safer medication.
• Antagonists: These substances bind to the mu-opioid receptor but do not activate it. Instead, they block it, preventing any agonist (full or partial) from binding and having an effect. This category includes naloxone and naltrexone.

Visualizing Receptor Activity and Respiratory Depression

A graph can help illustrate these concepts. Imagine the Y-axis represents the level of opioid effect (including respiratory depression) and the X-axis represents the dose.

• An antagonist (like naltrexone) would be a flat line at zero on the Y-axis. No matter how much you give, there is no opioid effect.
• A full agonist (like heroin or fentanyl) is a steep, upward-sloping line. As the dose increases, the effect continues to climb, eventually crossing the fatal threshold of respiratory depression.
• A partial agonist (like buprenorphine) starts by sloping upward, but then it levels off into a plateau or ceiling. This ceiling effect is the key to its safety profile.

FDA-Approved Medications for Opioid Use Disorder

The FDA approves three primary medications for the treatment of OUD. Each has a unique mechanism of action and clinical application.

1. Methadone

• Mechanism: Methadone is a long-acting full mu-opioid agonist. It is a Schedule II controlled substance.
• How it Works: By occupying and activating the opioid receptors, methadone relieves withdrawal symptoms and reduces cravings. Its long half-life (24-36 hours) allows for once-daily dosing, which provides stability and eliminates the need for the patient to seek illicit opioids.
• Administration: Due to federal regulations, methadone for OUD must be dispensed through a certified Opioid Treatment Program (OTP), or methadone clinic. Patients typically have to go to the clinic daily to receive their observed dose, though they may earn “take-home” privileges over time.
• Side Effects: Common side effects are typical of opioids: constipation, sedation, dizziness, nausea, and sweating.
• Serious Risks: The most significant risk is QTC prolongation, an electrical disturbance in the heart that can lead to a dangerous arrhythmia. The risk increases at higher doses (especially over 100 mg/day), so ECG monitoring is often recommended. As a full agonist, it also carries a risk of respiratory depression, particularly when combined with other sedatives like benzodiazepines or alcohol.

2. Buprenorphine

• Mechanism: Buprenorphine is a partial mu-opioid agonist and a kappa-opioid receptor antagonist. It is a Schedule III controlled substance.
• How it Works: Its genius lies in its unique pharmacology:

• • High Affinity: Buprenorphine has a very strong attraction, or affinity, for the mu-opioid receptor—stronger than that of full agonists like heroin or fentanyl. This means it can displace these other opioids from the receptor.
  • Partial Agonism & Ceiling Effect: Once bound, it only partially activates the receptor, providing enough of an effect to alleviate withdrawal and cravings without producing a significant “high.” Its ceiling effect provides a wide margin of safety against respiratory depression.

• The “Precipitated Withdrawal” Phenomenon: Because of its high affinity, if a person who has a full agonist (like heroin) in their system takes buprenorphine, the buprenorphine will “kick” the heroin off the receptors. This causes a sudden drop from a high level of receptor activation (from the heroin) to a lower level (from the buprenorphine), inducing a rapid and severe withdrawal syndrome known as precipitated withdrawal. This is why the standard protocol for initiating buprenorphine (“induction”) requires the patient to be in a state of moderate withdrawal first. At that point, receptor activation is low, and taking buprenorphine increases it, making them feel better.
• Formulations: It is available in various forms, most commonly as a sublingual film or tablet (e.g., Suboxone, which combines buprenorphine with naloxone) or as a once-monthly long-acting injection (Sublocade).
• Side Effects: Common side effects include headache, constipation, nausea, and oral numbness (hypoesthesia) from the sublingual formulations.
• Drug Interactions:

• • Benzodiazepines: While the combination increases the risk of sedation and respiratory depression, the FDA has issued a clear warning that the risks of withholding buprenorphine from a patient on a stable dose of benzodiazepines are far greater. The risk of them overdosing on illicit fentanyl is much higher than the risk of the prescribed combination. The two can be co-prescribed with careful monitoring and patient education.
  • CYP3A4 Inhibitors & Inducers: Buprenorphine is metabolized by the CYP3A4 enzyme. Inhibitors (like erythromycin or grapefruit juice) can increase buprenorphine levels, while inducers (like rifampin or St. John’s wort) can decrease them. This is an important consideration for dosing.

3. Naltrexone

• Mechanism: Naltrexone is a full mu-opioid receptor antagonist. It completely blocks the receptor.
• How it Works: By blocking the opioid receptors, naltrexone prevents any opioid from producing an effect. If a person on naltrexone uses heroin, they will not feel euphoria or any other effect. This can help reduce cravings over time by extinguishing the reward associated with use. It is also used for Alcohol Use Disorder.
• Administration: Naltrexone is available as a daily oral pill (50 mg) or, more commonly for OUD, as a long-acting monthly intramuscular injection called Vivitrol (380 mg).
• Induction Requirement: Because it is an antagonist, naltrexone will also precipitate severe withdrawal if given to someone with opioids in their system. Therefore, a patient must be completely opioid-free for 7-10 days before starting naltrexone. This opioid-free washout period can be a significant barrier for many patients.
• Side Effects: Common side effects include headache, nausea, diarrhea, and injection site reactions for the injectable form.
• Serious Risks: There is a risk of hepatotoxicity (liver damage), particularly at high doses, so monitor liver function. There are also warnings about depression and suicidality.
• Clinical Consideration: Patients must be counseled that naltrexone will block the effects of any opioid-based pain relief they might need in an emergency or for surgery. It also increases overdose risk if a person relapses after stopping naltrexone, as their tolerance will have decreased significantly.

The Role of Naloxone in Overdose Reversal

Naloxone (brand name Narcan) is an opioid antagonist that is a critical life-saving tool, but it is used for overdose reversal, not for the long-term treatment of OUD.

• Mechanism: When administered during an overdose, naloxone travels to the brain and, due to its high affinity, displaces the opioids that are causing respiratory depression from the mu-receptors. This immediately, though temporarily, reverses the overdose and restores breathing.
• Why to Call 911: Naloxone has a shorter half-life (30-90 minutes) than most opioids, especially long-acting ones like fentanyl. This means that as the naloxone wears off, the opioids still circulating in the person’s body can re-attach to the receptors and cause the overdose to resume. This is why it is absolutely critical to call emergency medical services immediately after administering naloxone. The person needs medical monitoring.
• Co-Prescribing: It is now standard practice and a strong recommendation for providers to co-prescribe naloxone to any patient who is taking opioids for pain, any patient with a history of OUD, and even patients who report using other illicit drugs, given the contaminated drug supply.
• Formulations: Naloxone is most commonly available as a pre-packaged intranasal spray (Narcan), which is easy for laypeople to use. It is also available in injectable forms used by EMS.
• Side Effects: The only “side effect” of naloxone is that it can induce opioid withdrawal in a physically dependent person. If given to someone with no opioids in their system, it has no effect.

A Commitment to Harm Reduction: Meeting Patients Where They Are

While abstinence-based recovery is a valid and worthy goal for many, it is not the only measure of success. Harm reduction is a pragmatic and compassionate public health approach that aims to reduce the negative health, social, and economic consequences associated with drug use, without necessarily requiring abstinence. It is about meeting people where they are and prioritizing their life and health above all else. In my practice, harm reduction is a key part of our comprehensive care strategy.

Here are some essential harm reduction strategies every provider should know and advocate for:

• Naloxone Distribution and Education: This is the most crucial harm reduction tool. We must ensure that our patients, their families, and their friends not only have naloxone but also know how to recognize an overdose and use it correctly.
• Fentanyl Test Strips: These are small, inexpensive strips of paper that can detect the presence of fentanyl in a drug supply. By providing these to patients, we empower them to test their drugs before using them. If a test is positive for fentanyl, they may choose not to use, to use less, or to ensure someone is with them who has naloxone. This is a powerful, life-saving intervention.
• Never Use Alone: We should counsel patients to avoid using drugs alone whenever possible. For those who must, the Never Use Alone Hotline (800-484-3731) is a vital resource. A person can call the hotline, and a volunteer will stay on the line with them while they use. If the person becomes unresponsive, the volunteer will call emergency services to their location.
• Clean Needle Exchanges (Syringe Service Programs): These programs provide sterile needles and syringes to people who inject drugs. This is a proven public health strategy that dramatically reduces the transmission of bloodborne pathogens like HIV and Hepatitis C. They also serve as critical access points where individuals can connect with other services, including wound care, testing, and entry into SUD treatment.
• Urine Drug Screens as a Harm Reduction Tool: While often used for monitoring compliance, we should reframe urine drug screens as a harm reduction and educational tool. When a screen comes back positive for a substance the patient was not aware of (e.g., fentanyl in their heroin), it is not a “gotcha” moment. It is an opportunity for a non-judgmental conversation: “It looks like the heroin you’ve been getting has fentanyl in it. That makes it much more dangerous. Let’s talk about how to keep you safe and reconsider starting buprenorphine.”
• Prescription Drug Monitoring Programs (PDMPs): These state-level electronic databases allow providers to see a patient’s prescription history for controlled substances. Using the PDMP is essential for coordinated and safe care, helping to prevent dangerous drug interactions and identify patients who may be struggling.
• Motivational Interviewing: As discussed extensively, MI is itself a form of harm reduction. It respects the patient’s autonomy and prioritizes their goals, whether that goal is abstinence, safer use, or simply staying alive for another day.

Conclusion

The journey through the history, science, and treatment of opioid use disorder is a complex one. We have seen how a class of drugs with ancient roots in pain relief has, through modern pharmacology and societal factors, fueled a devastating public health emergency.

My work as an integrative practitioner, blending chiropractic, functional medicine, and advanced practice nursing, is dedicated to addressing this crisis through a comprehensive, compassionate lens. Our collaborative model at Injury Medical Clinic, supported by Dr. Maria Cardenas’s deep medical expertise, allows us to treat the whole person—addressing structural pain with chiropractic care, biochemical imbalances with functional medicine, and the disease of addiction with evidence-based MOUD and psychological support.

We have learned that stigma remains a primary barrier to treatment and that we can actively dismantle it through our language and our actions. We have reviewed the evidence showing that MOUD is not a “crutch” but a life-saving, first-line medical treatment that reduces mortality by over 50%. We have embraced a philosophy of harm reduction that prioritizes the life and dignity of every patient, regardless of where they are on their recovery journey.

Treating opioid use disorder is a profound responsibility and a privilege. It requires a deep understanding of the disease’s pathophysiology, a commitment to evidence-based practice, and an unwavering belief in the potential for recovery. By integrating the best of all our disciplines, we can offer hope and healing to those affected by this crisis.

If you have any questions or wish to discuss this topic further, please do not hesitate to reach out.

References

• Centers for Disease Control and Prevention. (2023). Understanding the Opioid Overdose Epidemic.
• Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine, 9(5), 358–367.
• Miller, W. R., & Rollnick, S. (2013). Motivational Interviewing: Helping People Change (3rd ed.). The Guilford Press.
• National Institute on Drug Abuse. (2022). Opioid Overdose Crisis.
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.
• Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health.
• Volkow, N. D., & Blanco, C. (2020). The changing landscape of opioid use disorder. The New England Journal of Medicine, 382(22), 2085-2087.
• Wakeman, S. E., & Barnett, M. L. (2018). Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities. The New England Journal of Medicine, 379(1), 1–4.

SEO Tags: Opioid Use Disorder, OUD Treatment, Integrative Chiropractic Care, El Paso Chiropractor, Dr. Alex Jimenez, Dr. Maria Cardenas, Functional Medicine, Buprenorphine, Methadone, Naltrexone, Motivational Interviewing, Harm Reduction, Naloxone, Opioid Crisis, Substance Use Disorder, Pain Management, MOUD, Person-First Language, Stigma in Healthcare, Overdose Prevention, Injury Medical Clinic, Spinal Adjustments for Pain, Chronic Pain Treatment, Recovery Support, Neurobiology of Addiction